:" anf-ts-1"}], "layout":"default- body", "role": "body", "text":"An examination of Celgeneâe™s aggressive promotion of Revlimid and its predecessor, Thalomid, while Mr. Hugin was a top executive at the company, including its chief executive for six years, reveals many of the controversial financial and leg